Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-26T03:22:51.861Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital

Published online by Cambridge University Press:  04 January 2016

Keir Stone-Brown ,
Mahmood Naji ,
Alex Francioni ,
Kyle Myers ,
Harsh Samarendra ,
Haseeb Mushtaq-Chaudhry ,
Stephen Heslop ,
Samrat Sengupta ,
Callum C. Ross  and
Fintan Larkin
...Show all authors
Keir Stone-Brown
Affiliation:
School of Medicine, University of Manchester, Manchester, UK
Mahmood Naji
Affiliation:
Medical Sciences Division, John Radcliffe Hospital, University of Oxford, Oxford, UK
Alex Francioni
Affiliation:
Medical Sciences Division, John Radcliffe Hospital, University of Oxford, Oxford, UK
Kyle Myers
Affiliation:
Medical Sciences Division, John Radcliffe Hospital, University of Oxford, Oxford, UK
Harsh Samarendra
Affiliation:
Medical Sciences Division, John Radcliffe Hospital, University of Oxford, Oxford, UK
Haseeb Mushtaq-Chaudhry
Affiliation:
Broadmoor High Secure Hospital, West London Mental Health NHS Trust, London, UK
Stephen Heslop
Affiliation:
Broadmoor High Secure Hospital, West London Mental Health NHS Trust, London, UK
Samrat Sengupta
Affiliation:
Broadmoor High Secure Hospital, West London Mental Health NHS Trust, London, UK
Callum C. Ross
Affiliation:
Broadmoor High Secure Hospital, West London Mental Health NHS Trust, London, UK
Fintan Larkin
Affiliation:
Broadmoor High Secure Hospital, West London Mental Health NHS Trust, London, UK
Mrigendra Das*
Affiliation:
Broadmoor High Secure Hospital, West London Mental Health NHS Trust, London, UK
*
*Address for correspondence: Mrigendra Das, Broadmoor Hospital, Crowthorne, Berkshire, RG45 7EG, UK. (Email: mrigendra.das@wlmht.nhs.uk/mrigen.das@btinternet.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

To analyze antipsychotic prescribing patterns in a UK high security hospital (HSH) that treats seriously violent men with either schizophrenia or personality disorder and examine how different groups consented to treatment and prescribing for metabolic conditions. We hypothesized that there would be high prevalence of antipsychotic polypharmacy, and high-dose antipsychotic and clozapine prescribing.

Background

HSHs treat seriously violent, mentally disordered offenders, and the extant literature on prescribing patterns in forensic settings is sparse.

Methods

Prescribing and clinical data on all 189 patients in a UK HSH were collected from the hospital’s databases. Data were analyzed using SPSS.

Results

The population was split into the following groups: schizophrenia spectrum disorder (SSD-only), personality disorder (PD-only), and comorbid schizophrenia spectrum disorder and PD. The majority (93.7%) of all patients were prescribed at least one antipsychotic, and (27.5%) were on clozapine. Polypharmacy was prevalent in 22.2% and high-dose antipsychotic in 27.5%. Patients on clozapine were more likely to be prescribed antidiabetic, statins, or antihypertensive medication. Patients in the PD-only group were more likely to be deemed to have the capacity to consent to treatment and be prescribed clozapine in contrast to the SSD-only group.

Conclusions

Rates of clozapine and high-dose antipsychotic prescribing were higher than in other psychiatric settings, while polypharmacy prescribing rates were lower. Higher clozapine prescribing rates may be a function of a treatment-resistant and aggressive population. A higher proportion of PD-only patients consented to treatment and received clozapine compared with in-house SSD-only as well as other psychiatric settings. Implications of the findings are discussed.

Keywords

High security hospitalmentally disordered offenderspersonality disorderprescribingpsychotropic medicationsschizophreniaviolence
Type
Original Research
Information
CNS Spectrums , Volume 21 , Issue 1 , February 2016 , pp. 60 - 69
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Brown, D, Larkin, F, Sengupta, S, Romero-Ureclay, JL, Ross, CC, Gupta, N, Das, M. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr. 2014; 19(5): 391–402.CrossRefGoogle Scholar
2. Larkin, E, Murtagh, S, Jones, S. A preliminary study of violent incidents in a special hospital (Rampton). Br J Psychiatry. 1988; 153(2): 226–231.Google Scholar
3. Gordon, H, Grubin, D. Psychiatric aspects of the assessment and treatment of sex offenders. Advances in Psychiatric Treatment. 2004; 10(1): 73–80.Google Scholar
4. Rutherford, M, Duggan, S. Forensic mental health services: facts and figures on current provision. British Journal of Forensic Practice. 2008; 10(4): 4–10.Google Scholar
5. Blackburn, R, Logan, C, Donnelly, J, Renwick, S. Personality disorders, psychopathy and other mental disorders: co-morbidity among patients at English and Scottish high-security hospitals. Journal of Forensic Psychiatry & Psychology. 2003; 14(1): 111–137.Google Scholar
6. Thomas, S, Leese, M, Dolan, M, et al. The individual needs of patients in high secure psychiatric hospitals in England. Journal of Forensic Psychiatry & Psychology. 2004; 15(2): 222–243.Google Scholar
7. Stone, JH, Roberts, M, O’Grady, J, Taylor, AV, O’ Shea, K. Faulk’s Basic Forensic Psychiatry. Hoboken, NJ: Wiley; 1999.Google Scholar
8. Department of Health. Mental Health Act. London; 1983 rev. 2007; HMSO.Google Scholar
9. Hayhurst, K. Pennine Care NHS Trust Antipsychotic Prescribing Audit. Manchester, UK: The University of Manchester; 2006.Google Scholar
10. Harrington, M, Lelliott, P, Paton, C, Okocha, C, Duffett, R, Sensky, T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin. 2002; 26(11): 414–418.CrossRefGoogle Scholar
11. Stahl, SM. “The metabolic syndrome”: psychopharmacologists should weigh the evidence for weighing the patient. J Clin Psychiatry. 2002; 63(12): 1094–1095.Google Scholar
12. Gupta, A, Dadheech, G, Yadav, D, Sharma, P, Gautam, S. Metabolic issues in schizophrenic patients receiving antipsychotic treatment. Indian J Clin Biochem. 2014; 29(2): 196–201.Google Scholar
13. Ojala, K, Niskanen, L, Tiihonen, J, Paavola, P, Putkonen, A, Repo-Tiihonen, E. Characterization of metabolic syndrome among forensic psychiatric inpatients. Journal of Forensic Psychiatry & Psychology. 2008; 19(1): 33–51.Google Scholar
14. Taylor, PJ, Leese, M, Williams, D, Butwell, M, Daly, R, Larkin, E. Mental disorder and violence: a special (high security) hospital study. Br J Psychiatry. 1998; 172(3): 218–226.CrossRefGoogle ScholarPubMed
15. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Books & Pharmaceutical Press; 2015.Google Scholar
16. Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125(5): 349–351.CrossRefGoogle Scholar
17. Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013; 6(3): 97–100.Google Scholar
18. Stahl, SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002; 63(2): 93–94.CrossRefGoogle ScholarPubMed
19. Adams, CE, Fenton, MK, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001; 179(4): 290–299.Google Scholar
20. Barnes, TR, Shingleton-Smith, A, Paton, C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry. 2009; 195(52): S37–S42.Google Scholar
21. Gibbon, S, Silva, E, Kaler, R, et al. Risperidone long-acting injection (RLAI)—real world outcomes from the United Kingdom high-secure hospitals. The British Journal of Forensic Practice. 2011; 13(4): 264–269.Google Scholar
22. Baruch, N, Das, M, Sharda, A, et al. An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. Ther Adv Psychopharmacol. 2014; 4(5): 186–192.CrossRefGoogle Scholar
23. Walsh, E, Leese, M, Taylor, P, et al. Psychosis in high-security and general psychiatric services Report from the UK700 and Special Hospitals’ Treatment Resistant Schizophrenia groups. Br J Psychiatry. 2002; 180(4): 351–357.Google Scholar
24. Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 1351–1371.Google Scholar
25. Das, M, Barkataki, I, Kumari, V, Sharma, T. Neuroimaging violence in the mentally ill: what can it tell us? Hosp Med. 2002; 63(10): 604–609.CrossRefGoogle ScholarPubMed
26. Kumari, V, Das, M, Hodgins, S. Association between violent behaviour and impaired prepulse inhibition of the startle response in antisocial personality disorder and schizophrenia. Behav Brain Res. 2005; 158(1): 159–166.Google Scholar
27. Kumari, V, Soni, W, Sharma, T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry. 1999; 156(7): 1046–1051.CrossRefGoogle ScholarPubMed
28. Stahl, SM. Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectr. 2014; 19(4): 279–281.Google Scholar
29. Raedler, TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010; 23(6): 574–581.Google Scholar
30. Brown, D, Larkin, F, Sengupta, S, et al. Treatment of violent dissocial personality disorder patients with clozapine requires lower dose and therapeutic levels than in schizophrenia. Schizophrenia Research. 2014; 153(Suppl 1): S173.Google Scholar
31. Young, SL, Taylor, M, Lawrie, SM. “First do no harm”: a systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015; 29(4): 353–362.CrossRefGoogle ScholarPubMed
32. Hotham, JE, Simpson, PJ, Brooman-White, RS, et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectr. 2014; 19(5): 403–410.Google Scholar
33. Genç, Y, Taner, E, Candansayar, S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007; 24(1): 1–13.Google Scholar
34. Cipriani, A, Boso, M, Barbui, C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;■(3): CD006324.Google Scholar
35. Suzuki, T, Uchida, H, Takeuchi, H, et al. Augmentation of atypical antipsychotics with valproic acid: an open‐label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009; 24(8): 628–638.CrossRefGoogle ScholarPubMed
36. Ho, DK, Kottalgi, G, Ross, CC, Romero-Ulceray, J, Das, M. Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital. J Clin Psychopharmacol. 2012; 32(5): 739–740.Google Scholar
37. Zachariah, E, Kumari, V, Galea, A, et al. Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J Clin Psychopharmacol. 2002; 22(2): 224–226.Google Scholar
38. Ingenhoven, T, Lafay, P, Rinne, T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010; 71(1): 14–25.Google Scholar
39. Stahl, SM, Morrissette, DA, Cummings, M, et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr. 2014; 19(5): 449–465.Google Scholar